Welcome to our dedicated page for Acrivon Therapeutics news (Ticker: ACRV), a resource for investors and traders seeking the latest updates and insights on Acrivon Therapeutics stock.
Acrivon Therapeutics, Inc. (Nasdaq: ACRV) is a clinical stage biopharmaceutical company that regularly issues news about its precision oncology pipeline and Generative Phosphoproteomics AP3 platform. Company announcements describe progress for its lead CHK1/CHK2 inhibitor ACR-368 in a registrational-intent Phase 2 or Phase 2b trial in endometrial cancer, as well as updates on ACR-2316, a WEE1/PKMYT1 inhibitor in Phase 1 development, and AP3-enabled preclinical programs such as the CDK11-targeting candidate ACR-6840.
News releases from Acrivon often cover interim clinical data, including response rates and tumor shrinkage in AP3-prioritized solid tumor types, details on dose-escalation cohorts, and observations of drug target engagement based on AP3 profiling. The company also reports on regulatory designations, such as FDA Fast Track status for ACR-368 monotherapy in endometrial cancer and FDA Breakthrough Device designation for the ACR-368 OncoSignature assay, as well as trial design elements like biomarker-selected and biomarker-unselected arms and combinations with ultra-low dose gemcitabine.
Investors and observers following ACRV news can expect updates on Acrivon’s presentations at scientific conferences, including AACR and AACR-NCI-EORTC, where the company highlights AP3-based mechanistic data, the AP3 KaiSR generative AI model, and pharmacodynamic insights for ACR-2316 and other candidates. The company also issues periodic financial results and business highlights, summarizing cash resources, research and development activities, and anticipated clinical and regulatory milestones for its AP3-enabled pipeline.
This ACRV news page aggregates these press releases and related coverage, providing a centralized view of Acrivon’s reported clinical progress, platform developments, and corporate updates over time.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Acrivon Therapeutics, a clinical stage biopharmaceutical company, announced that CEO Peter Blume-Jensen will participate in a fireside chat on May 2, 2023, at 3:00 p.m. ET during the H.C. Wainwright BioConnect Investor Conference in New York. The company focuses on developing precision oncology medicines using its proprietary proteomics-based platform, known as Acrivon Predictive Precision Proteomics (AP3). Acrivon’s leading candidate, ACR-368, targets CHK1 and CHK2 and is in a Phase 2 trial for various tumor types. The OncoSignature® companion diagnostics, although not yet regulatory approved, aim to identify patients likely to benefit from ACR-368. Acrivon also explores preclinical programs targeting other nodes in DNA Damage Response, including WEE1 and PKMYT1.
Acrivon Therapeutics, a clinical-stage biopharmaceutical company (Nasdaq: ACRV), will host a virtual investor event on May 1, 2023, from 11:00 a.m. to 12:00 p.m. ET. The agenda includes a company overview, an update on the Acrivon Predictive Precision Proteomics (AP3) platform, details on the preclinical pipeline, clinical trial enrollment progress, and corporate updates.
The event can be accessed via the company’s investor website, and a replay will be available for 90 days. Acrivon focuses on precision oncology medicines, utilizing its AP3 platform for patient responder identification and developing the lead candidate ACR-368, targeting CHK1 and CHK2 in a Phase 2 trial across various tumor types. The company is also exploring additional preclinical programs targeting critical nodes in DNA Damage Response.
Acrivon Therapeutics, a clinical stage biopharmaceutical company, announced that its CEO, Peter Blume-Jensen, will participate in a fireside chat at the Stifel 2023 Targeted Oncology Days Conference on April 25, 2023, at 3:00 p.m. ET. This event will be held virtually and will focus on Acrivon’s advancements in precision oncology medicines.
Acrivon’s proprietary platform, AP3, matches patients’ tumor sensitivities to specific drugs. The company is advancing its lead candidate, ACR-368, targeting CHK1 and CHK2 in a Phase 2 trial. Acrivon also develops OncoSignature companion diagnostics to identify patients most likely to benefit from its drug candidates. A replay of the webcast will be available for 90 days after the event.
Acrivon Therapeutics (Nasdaq: ACRV) reported its financial results for Q4 and FY 2022, highlighting a net loss of $8.9 million for Q4 and $31.2 million for the full year, compared to losses of $4.3 million and $16.2 million in 2021.
The company successfully completed its IPO in November 2022 and initiated a Phase 2 trial for ACR-368 in patients with platinum-resistant cancers. Acrivon aims to advance precision oncology through its OncoSignature test and has made significant progress, including partnerships and team expansions. As of December 31, 2022, it had $169.6 million in cash, expected to fund operations through Q4 2024.
Acrivon Therapeutics, a clinical stage biopharmaceutical company, announced that CEO Peter Blume-Jensen will present an overview on March 13, 2023, at 3:20 p.m. ET during the Oppenheimer 33rd Annual Healthcare Conference. The presentation will be accessible via a live webcast on Acrivon's website. Acrivon focuses on developing precision oncology medicines using its proprietary AP3 platform, identifying patients whose tumors are sensitive to specific treatments. The company is advancing its lead candidate, ACR-368, a selective inhibitor targeting CHK1 and CHK2, in a Phase 2 trial across various tumor types. Acrivon’s OncoSignature companion diagnostics are in development to optimize patient treatment.